| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hind Yassmine Chennai, Salah Belaidi, Lotfi Bourougaa, Mebarka Ouassaf, Leena Sinha, Abdelouahid Samadi, Samir Chtit. Identification of Potent Acetylcholinesterase Inhibitors as New Candidates for Alzheimer Disease via Virtual Screening, Molecular Docking, Dynamic Simulation, and Molecular Mechanics-Poisson-Boltzmann Surface Area Calculations. Molecules (Basel, Switzerland). vol 29. issue 6. 2024-03-28. PMID:38542869. |
identification of potent acetylcholinesterase inhibitors as new candidates for alzheimer disease via virtual screening, molecular docking, dynamic simulation, and molecular mechanics-poisson-boltzmann surface area calculations. |
2024-03-28 |
2024-03-30 |
Not clear |
| Hind Yassmine Chennai, Salah Belaidi, Lotfi Bourougaa, Mebarka Ouassaf, Leena Sinha, Abdelouahid Samadi, Samir Chtit. Identification of Potent Acetylcholinesterase Inhibitors as New Candidates for Alzheimer Disease via Virtual Screening, Molecular Docking, Dynamic Simulation, and Molecular Mechanics-Poisson-Boltzmann Surface Area Calculations. Molecules (Basel, Switzerland). vol 29. issue 6. 2024-03-28. PMID:38542869. |
huperzine a (hup) plays a crucial role in alzheimer's therapy by enhancing cognitive function through increased cholinergic activity as a reversible acetylcholinesterase (ache) inhibitor. |
2024-03-28 |
2024-03-30 |
Not clear |
| Sabrina Lekmine, Ouided Benslama, Hichem Tahraoui, Mohammad Shamsul Ola, Aicha Laouani, Kenza Kadi, Antonio Ignacio Martín-García, Ahmad Al. Anti-Cholinergic Effects of the Phenolic Extract from the Pharmaceuticals (Basel, Switzerland). vol 17. issue 3. 2024-03-28. PMID:38543134. |
cholinesterase enzymes, namely, acetylcholinesterase (ache) and butyrylcholinesterase (bche), hold pivotal significance in alzheimer's disease (ad) treatment. |
2024-03-28 |
2024-03-30 |
Not clear |
| Mustafa Kemal Ozalp, Patricia A Vignaux, Ana C Puhl, Thomas R Lane, Fabio Urbina, Sean Ekin. Sequential Contrastive and Deep Learning Models to Identify Selective Butyrylcholinesterase Inhibitors. Journal of chemical information and modeling. 2024-03-27. PMID:38532612. |
butyrylcholinesterase (bche) is a target of interest in late-stage alzheimer's disease (ad) where selective bche inhibitors (bis) may offer symptomatic treatment without the harsh side effects of acetylcholinesterase (ache) inhibitors. |
2024-03-27 |
2024-03-29 |
Not clear |
| Xinyu Shan, Yichao Lu, Zhenyu Luo, Xiaoqi Zhao, Mei Pang, Hang Yin, Xuemeng Guo, Huanli Zhou, Junlei Zhang, Jiaxin Huang, Yingying Shi, Jinfang Lou, Lihua Luo, Jian Yo. A Long-Acting Lyotropic Liquid Crystalline Implant Promotes the Drainage of Macromolecules by Brain-Related Lymphatic System in Treating Aged Alzheimer's Disease. ACS nano. 2024-03-22. PMID:38517764. |
besides, by injecting a long-acting lyotropic liquid crystalline implant encapsulating cilostazol (an fda-approved selective pde-3 inhibitor) and donepezil hydrochloride (a commonly used symptomatic relief agent to inhibit acetylcholinesterase for alzheimer's disease) near the deep cervical lymph nodes of aged mice (about 20 months), an increase of lymphatic vessel coverage in the nodes and meninges was observed, along with accelerated drainage of macromolecules from brains. |
2024-03-22 |
2024-03-25 |
mouse |
| Varsha Mugundhan, Abirami Arthanari, Parameswari R Parthasarath. Protective Effect of Ferulic Acid on Acetylcholinesterase and Amyloid Beta Peptide Plaque Formation in Alzheimer's Disease: An In Vitro Study. Cureus. vol 16. issue 2. 2024-03-15. PMID:38487137. |
protective effect of ferulic acid on acetylcholinesterase and amyloid beta peptide plaque formation in alzheimer's disease: an in vitro study. |
2024-03-15 |
2024-03-17 |
Not clear |
| Varsha Mugundhan, Abirami Arthanari, Parameswari R Parthasarath. Protective Effect of Ferulic Acid on Acetylcholinesterase and Amyloid Beta Peptide Plaque Formation in Alzheimer's Disease: An In Vitro Study. Cureus. vol 16. issue 2. 2024-03-15. PMID:38487137. |
aim this study aims to comprehensively evaluate the effects of ferulic acid (fa) on acetylcholinesterase (ache) enzyme activity and amyloid beta (aβ) peptide plaque formation in an in vitro model of alzheimer's disease (ad). |
2024-03-15 |
2024-03-17 |
Not clear |
| Olivia Wyse Faria, Mayara Sandrielly Soares de Aguiar, Julia Eisenhardt de Mello, Fernando Lopez Alvez, Karina Pereira Luduvico, Driele Neske Garcia, Augusto Schneider, Michal M Masternak, Roselia Maria Spanevello, Francieli Moro Stefanell. Senolytics prevent age-associated changes in female mice brain. Neuroscience letters. 2024-03-14. PMID:38485080. |
considering that the combination of dasatinib and quercetin (d + q) demonstrated a neuroprotective, as well as that females experience a decline in hormonal levels during aging and this is linked to increased susceptibility to alzheimer's disease, in this study we evaluated the effect of d + q on inflammatory and oxidative stress markers and on acetylcholinesterase and na |
2024-03-14 |
2024-03-17 |
mouse |
| Yaqi Gao, Yulin Liu, Yanfang L. Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer's disease: A systematic review and meta-analysis. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2024-03-05. PMID:38439609. |
safety and efficacy of acetylcholinesterase inhibitors for alzheimer's disease: a systematic review and meta-analysis. |
2024-03-05 |
2024-03-07 |
Not clear |
| Bong-Jo Kim, Seon-Been Bak, Su-Jin Bae, Hyo-Jung Jin, Sang Mi Park, Ye-Rim Kim, Dae-Hwa Jung, Chang-Hyun Song, Young-Woo Kim, Sang-Chan Kim, Won-Yung Lee, Sun-Dong Par. Protective Effects of Red Ginseng Against Tacrine-Induced Hepatotoxicity: An Integrated Approach with Network Pharmacology and Experimental Validation. Drug design, development and therapy. vol 18. 2024-02-29. PMID:38419811. |
tacrine, an fda-approved acetylcholinesterase inhibitor, has shown efficacy in treating alzheimer's disease, but its clinical use is limited by hepatotoxicity. |
2024-02-29 |
2024-03-02 |
Not clear |
| Franziska Pohl, Victoria Lindsay-McGee, Paul Kong Thoo Lin, Patricia Maciel, Andreia Teixeira-Castr. Pharmacological inhibition of acetylcholinesterase improves the locomotion defective phenotype of a SCA3 microPublication biology. vol 2024. 2024-02-26. PMID:38404918. |
pharmacological inhibition of acetylcholinesterase improves the locomotion defective phenotype of a sca3 inhibition of acetylcholinesterase (ache) is a common used treatment option for alzheimer's disease. |
2024-02-26 |
2024-02-28 |
Not clear |
| Panthip Tue-Ngeun, Waleepan Rakitikul, Natechanok Thinkumrob, Supa Hannongbua, Wijitra Meelua, Jitrayut Jitonno. Binding interactions and in silico ADME prediction of isoconessimine derivatives as potent acetylcholinesterase inhibitors. Journal of molecular graphics & modelling. vol 129. 2024-02-24. PMID:38401250. |
in pursuit of new acetylcholinesterase (ache) inhibitors for treating alzheimer's disease (ad), a series of ten previously synthesized isoconessimine compounds (7a-7j) was in silico investigated for their binding interactions with ache and pharmacokinetics based on absorption, distribution, metabolism, and excretion (adme) properties using molecular docking, oniom (our own n-layered integrated molecular orbital and molecular mechanics) method and swissadme tools. |
2024-02-24 |
2024-02-27 |
Not clear |
| Efe Doğukan Dincel, Faika Başoğlu-Ünal, Ebru Didem Kuran, Tülay Kayra, Nurcan Aydın, Esmanur Kanber, İlhami Gülçin, Nuray Ulusoy-Güzeldemirc. Design, synthesis, and evaluation of novel bistrifluoromethyl-based hydrazones as dual inhibitors of acetylcholinesterase and carbonic anhydrase enzymes for Alzheimer's disease. Chemical biology & drug design. vol 103. issue 2. 2024-02-20. PMID:38378259. |
design, synthesis, and evaluation of novel bistrifluoromethyl-based hydrazones as dual inhibitors of acetylcholinesterase and carbonic anhydrase enzymes for alzheimer's disease. |
2024-02-20 |
2024-02-23 |
human |
| Varish Ahmad, Ibrahim Alotibi, Anwar A Alghamdi, Aftab Ahmad, Qazi Mohammad Sajid Jamal, Supriya Srivastav. Computational Approaches to Evaluate the Acetylcholinesterase Binding Interaction with Taxifolin for the Management of Alzheimer's Disease. Molecules (Basel, Switzerland). vol 29. issue 3. 2024-02-10. PMID:38338420. |
computational approaches to evaluate the acetylcholinesterase binding interaction with taxifolin for the management of alzheimer's disease. |
2024-02-10 |
2024-02-12 |
Not clear |
| Yi-Long Lu, Jing Su, Jian-Wei Li, Wen-Rong X. A molecular container providing supramolecular protection against acetylcholine hydrolysis. Organic & biomolecular chemistry. 2024-02-07. PMID:38323382. |
alzheimer's disease (ad) is characterized by cognitive decline, often attributed to the deficiency of acetylcholine, which can undergo hydrolysis by acetylcholinesterase (ache) within the biological milieu. |
2024-02-07 |
2024-02-09 |
Not clear |
| Bikram Saha, Agnidipta Das, Kailash Jangid, Amit Kumar, Vinod Kumar, Vikas Jaita. Identification of coumarin derivatives targeting acetylcholinesterase for Alzheimer's disease by field-based 3D-QSAR, pharmacophore model-based virtual screening, molecular docking, MM/GBSA, ADME and MD Simulation study. Current research in structural biology. vol 7. 2024-01-31. PMID:38292820. |
identification of coumarin derivatives targeting acetylcholinesterase for alzheimer's disease by field-based 3d-qsar, pharmacophore model-based virtual screening, molecular docking, mm/gbsa, adme and md simulation study. |
2024-01-31 |
2024-02-02 |
Not clear |
| Dhairiya Agarwal, Sumit Kumar, Ramesh Ambatwar, Neeru Bhanwala, Lokesh Chandrakar, Gopal Khati. Lead Identification Through In Silico Studies: Targeting Acetylcholinesterase Enzyme Against Alzheimer's Disease. Central nervous system agents in medicinal chemistry. 2024-01-30. PMID:38288823. |
lead identification through in silico studies: targeting acetylcholinesterase enzyme against alzheimer's disease. |
2024-01-30 |
2024-02-01 |
Not clear |
| Dhairiya Agarwal, Sumit Kumar, Ramesh Ambatwar, Neeru Bhanwala, Lokesh Chandrakar, Gopal Khati. Lead Identification Through In Silico Studies: Targeting Acetylcholinesterase Enzyme Against Alzheimer's Disease. Central nervous system agents in medicinal chemistry. 2024-01-30. PMID:38288823. |
in this work, we aimed to acquire the best potential small molecule for alzheimer's disease (ad) treatment using different models in biovia discovery studio to identify new potential inhibitors of acetylcholinesterase (ache) via in silico studies. |
2024-01-30 |
2024-02-01 |
Not clear |
| Ashish Kumar, Fred Kim, Dong-Keun Song, Jai Jun Choun. Polypharmacological Potential of Phosphodiesterase 5 Inhibitors for the Treatment of Neurocognitive Disorders. Aging and disease. 2024-01-25. PMID:38270120. |
for alzheimer's disease (ad), one of the most studied ncd, approved drugs include acetylcholinesterase inhibitors (rivastigmine, donepezil, and galantamine), an nmda receptor antagonist (memantine), and anti-amyloid monoclonal antibodies (aducanumab and lecanemab). |
2024-01-25 |
2024-01-27 |
Not clear |
| Swati Singh, Divya Bhatt, Munmun Kumar Singh, Surbhi Bisht, Velusamy Sundaresan, Rajendra Chandra Padalia, Dnyaneshwar U Bawankule, Ram Swaroop Verm. Neuroinflammation and Acetylcholinesterase Inhibitory Potentials of a Spiroketal-Enol Ether Polyyne Isolated from Artemisia pallens Wall. ex DC. Chemistry & biodiversity. 2024-01-24. PMID:38263615. |
the results showed that d6 has a potential role in the resolution of neuroinflammation, and its acetylcholinesterase inhibitory potential directs further investigation of its role in the management of alzheimer's disease-related pathogenesis. |
2024-01-24 |
2024-01-26 |
Not clear |